[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"countryName\":\"Sierra Leone\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":245},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,44,87,117,159,188,216],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":26,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100626750","icu-related-out-of-pocket-expenses-icope-100626750",false,"NCT07439692","ICU-related Out of Pocket Expenses (ICOPE)","ICU-related Out of Pocket Expenses (ICOPE) - A Multinational Prospective Study In African And Asian Countries.","ICOPE","Inclusion Criteria:\n\nAll patients admitted to the participating ICUs during a predefined window of 14 days and expected to have a duration of stay \\>24 hours will be eligible for the study.\n\nExclusion Criteria:\n\nlack informed consent.","ALL",{"count":19,"type":20},354,"ESTIMATED","OBSERVATIONAL","The ICU-related Out-of-Pocket Expenses (ICOPE) study is a multinational, prospective observational study conducted in African and Asian countries to quantify ICU-related out-of-pocket expenditures and catastrophic health expenditure among patients and families. The study will include all patients admitted to participating ICUs during a predefined 14-day recruitment window, provided they have an ICU stay longer than 24 hours and informed consent is obtained. A minimum sample size of 354 patients is planned, including both ventilated and non-ventilated patients. Participants will be followed until ICU discharge, with additional follow-up at 30 days and 6 months after admission, resulting in a total study duration of 18 months. The primary objective is to quantify ICU-related out-of-pocket costs and assess the proportion of patients experiencing catastrophic health expenditure, comparing ventilated and non-ventilated groups, while secondary objectives include identifying risk factors for catastrophic expenditure and documenting coping strategies used by families to manage ICU costs.",[24,25],"Cost of ICU","Out of Pocket Expenses",[27,28,29,30],"OOPE","ICU-cost","LMIC","Critical Care","RECRUITING","2026-02-23",{"date":34,"type":35},"2026-02-27","ACTUAL",{"date":37,"type":35},"2024-12-01",{"date":39,"type":20},"2026-07-31",{"name":41,"class":42},"Nat Intensive Care Surveillance - MORU","OTHER",44,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":86},"100616295","phase-2-study-assessing-reduced-hpv-infectivity-and-transmission-in-hpv-positive-women-following-vaccination-with-9vhpv-100616295","NCT07303751","Study Assessing Reduced HPV Infectivity and Transmission in HPV-Positive Women Following Vaccination With 9vHPV","HPV Vaccination and Infectivity Reduction in HPV-positive Women","RIFT-SSA","Inclusion Criteria:\n\n* Born female\n* Aged between 18-29 years old;\n* Living in Kambia district (or neighbouring district if included) without plans to move away in the next 12 months;\n* Willing to participate in the study and have signed the informed consent form;\n* In good health as determined by a medical history (a physical examination will be conducted if necessary according to the clinician's judgement);\n* Willing to be tested for HIV;\n* Are HIV negative at the screening visit;\n* Not pregnant;\n* Able to pass a Test of Understanding (TOU);\n* Willing to provide cervical, urine and blood samples;\n* Agree to be vaccinated with a single dose of Gardasil9® if randomised to the vaccine arm at Day 0;\n* Have no visible suspicious cervical lesions on examination.\n* Agree to a pregnancy test at screening and before any HPV vaccination.\n\nExclusion Criteria:\n\n* They have been previously vaccinated against HPV;\n* They have a chronic condition, such as autoimmune conditions, degenerative diseases, neurologic or genetic diseases among others;\n* They are HIV positive or immunocompromised;\n* They are pregnant or planning to get pregnant in the next 12 months;\n* They are less than three months post-partum or currently breastfeeding;\n* They are allergic to one of the vaccine components or to latex;\n* They are sexually active and are not using, or are not willing to use, an effective birth control method from D-14 until 60 days after the last vaccine dose\n* The nurse or clinician determining the eligibility, in agreement with principal investigator, considers that there is a reason that precludes participation.","FEMALE","18 Years","29 Years",{"count":56,"type":20},80,"INTERVENTIONAL",[59],"PHASE2","This is a randomized, open-label trial, to assess whether a single dose of HPV nonavalent vaccine, administered to HIV uninfected, unvaccinated women with high risk HPV16\u002F18\u002F31\u002F33\u002F45\u002F52 or 58 can decrease the infectivity of shed HPV viruses.\n\nOur hypothesis is that vaccination will have little or no impact on HPV sample positivity by DNA PCR since the viral particles will continue to be produced and released, but that particles will be neutralized by vaccine-induced antibodies, thereby reducing their infective capacity. Cervical samples will be collected at randomisation and at 6 months, to compare infectivity of shed HPV viruses.",[62,63,64],"HPV","High-risk HPV (Any Strain)","Human Papillomavirus (HPV) Infections",[66,67,68,64,69,70,71,72,73,74,75],"Cervical cancer","Cervical Intraepithelial Neoplasia Grade I\u002F II\u002F III (CIN I\u002FII\u002FIII)","Squamous Intraepithelial Lesions of the Cervix, High\u002F Low Grade","High-risk HPV","HPV-16\u002F 18","HPV DNA Tests","HPV Vaccines","HPV Nonavalent Vaccine","Gardasil-9","9vHPV","NOT_YET_RECRUITING","2026-02-09",{"date":79,"type":35},"2026-02-11",{"date":81,"type":20},"2026-02-01",{"date":83,"type":20},"2027-02-01",{"name":85,"class":42},"Institut d'Investigació Biomèdica de Bellvitge",1,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":95,"targetDuration":4,"studyType":57,"phases":97,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":116},"100580769","phase-3-ebola-post-exposure-prophylaxis-100580769","NCT06841614","EBOla Post-Exposure Prophylaxis","Evaluation of the Efficacy of a Post-exposure Prophylaxis (PEP) Strategy in Contacts at High Risk of Developing Ebola Virus Disease (EVD)","EBO-PEP","Inclusion criteria\n\n* Last high-risk contact within the last 5 days\n* No sign or symptoms of EVD\n* Signed and dated informed consent from participants over the age of majority to participate in the trial or from a representative of parental authority for minor participants.\n\nNon-inclusion criteria\n\n* History of vaccination with Ervebo or any other EVD vaccine within the last 5 years (self-reported by the participant)\n* History of confirmed EVD within the last 5 years (self-reported by the participant)\n* Hypersensitivity to any of the experimental medical products (IMP) or their excipients (self-reported by the participant)\n* Participation in another therapeutic or vaccine trial for EVD\n* Any other reason that, at the investigator's discretion, could compromise the participant's safety and cooperation in the trial.",{"count":96,"type":20},160,[98],"PHASE3","EBO-PEP is a multicentre, multi-epidemic, phase III, comparative, controlled, randomised, strict superiority trial in two unblinded parallel arms.\n\nThe trial will be open during EVD epidemics and will recruit asymptomatic participants at high risk of developing EVD.\n\nParticipants will be randomized (1:1) into one of two trial arms:\n\n* Arm 1 (ERV): Ervebo D0 (72 million PFU IM)\n* Arm 2 (ERV+IMZ): Ervebo D0 (72 million PFU IM) + Inmazeb IV (150 mg\u002Fkg) D0 + Ervebo D56 (revaccination)\n\nDefinition of high-risk:\n\nDirect contact with a person with EBOV PCR-confirmed EVD with diarrhea, vomiting or external bleeding (\"wet symptoms\"), or with their body fluids; Direct contact with the dead body of a person with confirmed or probable EVD; Needlestick with a syringe contaminated by the blood of a person with confirmed or probable EVD; Or a child born to or breastfed by an individual with EVD\n\nTrial follow-up All participants are monitored daily for a minimum of 21 days.\n\nSome visits are conducted in person at the investigation site, also called the Post-Exposure Prophylaxis (PEP) center:\n\n* at Day 5, Day 10, and Day 21 for the ERV arm,\n* at Day 5, Day 10, Day 21, and Day 56 for the ERV+IMZ arm. Other visits are conducted at home or by phone, in collaboration with the Ministry of Health's surveillance team.\n\nParticipants in the ERV+IMZ arm have an in-person visit at Day 56 to be revaccinated with the Ervebo vaccine to compensate for potential inhibition of the vaccine response when Ervebo is administered simultaneously with Inmazeb.\n\nParticipants in the ERV arm have a phone visit at Day 56. For all participants, a phone visit is scheduled at Day 60. It corresponds to the last visit for all trial participants.\n\nFollow-up in Case of Hospitalisation In case of clinical signs suggestive of EVD, participants enter the suspected case management pathway at the Ebola Treatment Center (ETC).\n\nIf EVD is confirmed by EBOV PCR, participants are allowed at the ETC, and their study samples are discontinued. They continue to be followed by the research team, and daily data are collected throughout their stay at the ETC until they are discharged alive or deceased. The day of discharge from the ETC marks the end of follow-up in the study for these participants.\n\nOf note, participants in the ERV+IMZ arm who have confirmed EVD are not revaccinated at day 56.\n\nOf note, participants in the ERV+IMZ arm who have confirmed EVD are not revaccinated at day 56.\n\nIf EVD is not confirmed, participants continue to be followed up by the PEP center according to the protocol.",[101],"Ebola Virus Disease",[101,103,104,105],"EBOV","High-Risk contact","Post-Exposure Prophylaxis","2026-01-21",{"date":108,"type":35},"2026-01-22",{"date":110,"type":20},"2026-09",{"date":112,"type":20},"2028-08-01",{"name":114,"class":115},"ANRS, Emerging Infectious Diseases","OTHER_GOV",4,{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":125,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":57,"phases":129,"briefSummary":131,"conditions":132,"keywords":137,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100582940","milk-fat-globule-membrane-enhanced-rutf-for-children-with-severe-acute-malnutrition-100582940","NCT06869850","Milk Fat Globule Membrane-Enhanced RUTF for Children With Severe Acute Malnutrition","MFGM-EnhaNceD RUTF for Children With SAM","MEND-SAM","Inclusion Criteria:\n\n* 6-59 months of age\n* Reside within the catchment area of a participating clinic\n* mid-upper arm circumference \\\u003C 11.5 cm and\u002For weight-for-length z-score \\\u003C -3 and\u002For presence of bilateral pedal pitting edema\n* willingness to comply with all study procedures and availability for the duration of the study, including no plan to move from the catchment area of a participating clinic\n\nExclusion Criteria:\n\n* Features of complicated SAM: inability to tolerate a 30 g test dose of RUTF, breathing difficulties, mental status changes, sepsis, diarrhea with severe dehydration, and\u002For physician\u002Fnursing clinical assessment that the child needs immediate hospitalization\n* Participation in a separate therapeutic feeding program within the past month\n* Known allergy to study food ingredient (peanut, milk, fish)\n* Clinically evident developmental delay (most often determined based on research nursing assessment of physical appearance, movement, and informal discussion with caregiver)\n* Presence of a chronic severe medical condition (other than tuberculosis and HIV), such as congenital heart disease","6 Months","59 Months",{"count":128,"type":20},1600,[130],"NA","The goal of this clinical trial is to test the use of milk fat globule membrane (MFGM) in ready-to-use therapeutic food (RUTF) in children with severe acute malnutrition in Sierra Leone. The main questions it aims to answer are:\n\n* Will the inclusion of MFGM in RUTF for 6-59-month-old Sierra Leonean children with severe acute malnutrition improve their neurodevelopment?\n* Will the inclusion of MFGM in RUTF for 6-59-month-old Sierra Leonean children with severe acute malnutrition reduce its worst consequences: death, hospitalization, and remaining severely malnourished despite treatment?\n\nResearchers will compare the MFGM-containing RUTF to standard RUTF, which contains skim milk powder.\n\nParticipants will:\n\n* undergo measurement of length, weight, mid-upper arm circumference, and nutritional edema assessment every two weeks during severe malnutrition treatment\n* be treated with either MFGM-RUTF or standard RUTF at a dose of 2 sachets per day for up to 12 weeks\n* undergo neurodevelopmental testing using the Malawi Developmental Assessment Tool at the end of SAM treatment and 6 months later\n* a subset of participants will undergo blood spot collection and stool sample collection",[133,134,135,136],"Severe Acute Malnutrition","Cognitive Impairment","Kwashiorkor","Severe Wasting",[138,139,140,141,142,143,144,145,146,147,148],"severe acute malnutrition","severe wasting","kwashiorkor","milk fat globule membrane","neurodevelopment","phospholipids","ganglioside","dairy fat","malawi developmental assessment tool","Sierra Leone","ready-to-use therapeutic food","2025-12-16",{"date":151,"type":35},"2025-12-17",{"date":153,"type":35},"2025-09-22",{"date":155,"type":20},"2027-12-01",{"name":157,"class":42},"Washington University School of Medicine",10,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":57,"phases":169,"briefSummary":170,"conditions":171,"keywords":173,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":187},"100483871","phase-3-reducing-mortality-in-adults-with-advanced-hiv-disease-revive-100483871","NCT05580666","Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)","Reducing Mortality in Adults With Advanced HIV Disease, a Double Blinded Randomized Trial","REVIVE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Documented HIV infection\n3. CD4 count criteria:\n\n   i. CD4 count ≤ 100 cells\u002Fmm3 within past 4 weeks; or\n\n   ii. Documented CD4 nadir ≤ 100 cells\u002Fmm3 and complete interruption of ART for ≥ 6 months; or\n\n   iii. Documented CD4 count ≤ 100 cells\u002Fmm3 if ART-naive\n4. Ability to initiate or re-initiate ART, or switch to an effective ART regimen if failing current therapy, within 4 weeks of enrolment\n\nExclusion Criteria:\n\n1. Contraindications to azithromycin:\n\n   i. Hypersensitivity to azithromycin, erythromycin, or any macrolide antibiotic; or\n\n   ii. Personal or family history of QT-prolongation\n2. Severe illness requiring immediate or continued hospitalization (this will be in the judgment of site investigators)\n3. Off-label azithromycin prophylaxis or requirement for prolonged (\\> 7 days) azithromycin (or macrolide) therapy",{"count":168,"type":20},8000,[98],"A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.",[172],"HIV Disease Progression",[174,175,176,177],"Human immunodeficiency virus","Antiretroviral therapy","Azithromycin","Mortality","2025-08-26",{"date":180,"type":35},"2025-09-03",{"date":182,"type":35},"2023-05-08",{"date":184,"type":20},"2029-05-31",{"name":186,"class":42},"Population Health Research Institute",52,{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":192,"acronym":62,"eligibilityCriteria":193,"healthyVolunteers":194,"sex":52,"minAge":195,"maxAge":196,"enrollmentInfo":197,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":215},"100526016","global-burden-estimation-of-human-papillomavirus-globe-hpv-100526016","NCT06129253","Global Burden Estimation of Human Papillomavirus (GLOBE-HPV)","Inclusion Criteria:\n\n1. 9 to 50 years old (for urban and rural CSSs) at the time of enrollment.\n2. Resident in the selected community for at least the past 3 months (with the exception of pastoralists, refugees, and commercial sex workers).\n3. Able to understand the purpose of the study and study procedures.\n4. If aged 18 years or older or legally considered an emancipated minor, able and willing to provide consent to participate in the study including sample collection.\n5. If aged \\\u003C18 years (and not considered an emancipated minor), supported in their participation by a parent or guardian who is able and willing to provide consent, and\n6. If aged \\\u003C18 years (and not considered an emancipated minor), able and willing to provide assent to participate in the study.\n\nExclusion Criteria:\n\n1. Decline consent to participate any activity of the study.\n2. A medical condition or other reason, not directly related to HPV infection or HPV-related diseases, in the opinion of the investigator, precludes enrolment in the study.",true,"9 Years","50 Years",{"count":198,"type":20},29750,"This study is a multi-country and multi-site project to estimate the point-prevalence of high-risk (HR) HPV genotype infections among representative samples of girls and women aged 9-50 years, and among specific sub-populations to estimate the incidence of persistent HPV infection among sexually active young women. The data to fulfill the objectives will be collected through a series of Cross-Sectional Surveys (CSS) and Longitudinal Studies (LS) in all 8 countries 3 South Asian countries including Bangladesh, Pakistan, Nepal and 5 sub-Saharan African countries including Sierra Leone, Tanzania, Ghana, Zambia and DR Congo. Qualitative sub-studies (QS) will be conducted in selected countries and populations following the CSS to further understand and unpack risk factors for HPV infection as well as to explore how gender-related dynamics including perceptions of gender norms and stigma, influence HPV burden and\u002For create barriers that shape girls\u002Fwomen access to and uptake of HPV prevention, screening, and treatment services. Specific study protocols and corresponding ethical applications for the qualitative sub-studies will be developed separately.",[201],"HPV Infection",[203,201,204,205],"HPV Positivity","High Risk (HR) HPV","Cervical Cancer","2025-07-15",{"date":208,"type":35},"2025-07-16",{"date":210,"type":35},"2023-11-23",{"date":212,"type":20},"2027-12",{"name":214,"class":42},"International Vaccine Institute",8,{"id":217,"slug":218,"hasResults":11,"nctId":219,"briefTitle":220,"officialTitle":221,"acronym":222,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":224,"targetDuration":4,"studyType":57,"phases":226,"briefSummary":228,"conditions":229,"keywords":233,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":243,"locationsCount":86},"100508340","phase-4-adjunctive-clindamycin-for-the-treatment-of-skin-and-soft-tissue-infections-a-randomized-controlled-trial-100508340","NCT05899140","Adjunctive Clindamycin for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled Trial","Adjunctive Clindamycin Versus Standard of Care for the Treatment of Skin and Soft Tissue Infections, a Randomized Controlled, Open-label Superiority Phase 4 Trial","SoTiClin","Inclusion Criteria:\n\n1. Adults (age ≥18 years);\n2. Need for a treatment (incision\u002Fdrainage ± antibiotic treatment po or iv) of an SSTI;\n3. S. aureus causing SSTI identified from at least one clinical specimen (including isolation in polymicrobial cultures if S. aureus is considered to be the leading pathogen);\n4. Onset of symptoms within the last 4 weeks;\n5. Randomisation possible within 72 hours from collection of the initial culture\n6. Ability to conduct the follow-up visits either during admission or at home\n7. Initial culture collected within 48 hours of hospital admission\n8. Willingness to participate in the study.\n\nExclusion Criteria\n\n1. Previous allergic reaction to clindamycin\n2. Previous antibiotic-associated diarrhea\n3. Previous study participation\n4. Pregnancy as confirmed by a beta-HCG rapid test.\n5. Started treatment with clindamycin prior to clinic presentation;\n6. Documented systemic antibiotic treatment within the previous 14 days\n7. Co-administration of other protein synthesis inhibitors (e.g. macrolides, rifampicin, linezolid, aminoglycosides, tetracyclines, chloramphenicol);\n8. Co-administration of toxin inducers (trimethoprim-sulfamethoxazole)\n9. Severe illness (patient expected to die in the following 24 hrs);\n10. Chronically infected wounds (\\>4 weeks of symptoms);\n11. Infections associated with any of the following (due to mixed infection): a) Human or animal bites;b) Prosthetic or implantable devices; c) Decubitus ulcers; d) Diabetic foot ulcers, infected ulcers secondary to peripheral artery disease, chronic venous insufficiency; e) Suspected Buruli ulcer; f) Infected burns.\n12. Hospital-acquired infection including post-surgical site infections",{"count":225,"type":20},100,[227],"PHASE4","This is an exploratory study to evaluate the effect of adjunctive clindamycin in the treatment of skin and soft-tissue infections due to Staphylococcus aureus in patients from Sierra Leone. The study hypothesizes that clindamycin, when added to routine treatment, will lead to a more rapid clinical resolution and less frequent recurrences of infection.",[230,231,232],"Skin Infection","Staphylococcal Infections","Staphylococcus Aureus Infection",[234,235,236],"SSTI","Staphylococcus aureus","Panton-Valentine leukocidin","2024-12-04",{"date":239,"type":35},"2024-12-09",{"date":241,"type":35},"2024-03-15",{"date":39,"type":20},{"name":244,"class":42},"Frieder Schaumburg",""]